All Dopavision Articles
-
468Latest Myopia NewsDopavision Completes Enrollment for MyopiaX-1 Trial
September 26, 2023 BERLIN, Germany — Dopavision has successfully completed enrollment for its MyopiaX-1 clinical trial. MyopiaX-1 is a randomized, active-controlled trial...
-
893Latest Myopia NewsDopavision Announces All MyopiaX-1 Clinical Trial Sites are Active
June 28, 2023 BERLIN, Germany — Dopavision’s MyopiaX-1 clinical trial centers are now all active, screening and enrolling participants across Germany, Spain,...
-
1.5KIn The PipelineProf. Dr. Jens Ellrich Named Chief Scientific Officer at Dopavision
March 21, 2023 BERLIN, Germany — Professor Dr. Jens Ellrich has been named the new Chief Scientific Officer at Dopavision, a clinical-stage...
-
630Latest Myopia NewsDirk Sauer Named Chairman of Dopavision’s Advisory Board
November 17, 2022 BERLIN, Germany — Dr. Dirk Sauer has been named the Chairman of Dopavision’s Advisory Board. Dr. Sauer brings a track...
-
955Latest Myopia NewsMark S. Wuttke Named CEO of Dopavision
May 25, 2022 BERLIN — Dopavision has officially named a new CEO, Mark S. Wuttke, PhD. He succeeds Dopavision’s co-founder and previous...
-
1.6KIn The PipelineA Smartphone-Based Treatment for Childhood Myopia
November 15, 2021 By Hamed Bahmani, BEng, MSc, PhD A smartphone application, MyopiaX is a non-invasive digital treatment designed to achieve a...
-
2.1KLatest Myopia NewsDopavision Closes €12 Million Series A Financing for Myopia Clinical Trials
July 14, 2021 BERLIN — Dopavision has completed €12 million Series A financing to further clinical trials geared toward therapies for childhood...